Ezetimibe and Improving Cardiovascular Outcomes: Current Evidence and Perspectives
Low-density lipoprotein lowering with statins has convincingly and consistently proven to reduce cardiovascular events in both primary and secondary prevention. However, despite high-dose statin therapy, residual cardiovascular risk remains and many patients also do not tolerate statins. Ezetimibe w...
Saved in:
Main Authors: | Akshyaya Pradhan, Monika Bhandari, Rishi Sethi |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-01-01
|
Series: | Cardiology Research and Practice |
Online Access: | http://dx.doi.org/10.1155/2020/9815016 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Spectrophotometric Determination of Ezetimibe
by: P. Baby Sudha Lakshmi, et al.
Published: (2010-01-01) -
Ezetimibe: An Unusual Suspect in Angioedema
by: Tiffany Lu, et al.
Published: (2020-01-01) -
Clinical and Radiological Presentations of Various Pulmonary Infections in Hospitalized Diabetes Mellitus Patients: A Prospective, Hospital-Based, Comparative, Case Series Study
by: Pravesh Vishwakarma, et al.
Published: (2021-01-01) -
Ezetimibe Anticancer Activity via the p53/Mdm2 Pathway
by: Charmy Twala, et al.
Published: (2025-01-01) -
Ezetimibe Improves Rosuvastatin Effects on Inflammation and Vascular Endothelial Function in Acute Coronary Syndrome Patients Undergoing PCI
by: Changqing Sun, et al.
Published: (2021-01-01)